This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:protocol:olmesartan:kidney_disease [11.07.2018] – [Benefits of olmesartan for patients with kidney disease] sallieq | home:protocol:olmesartan:kidney_disease [08.13.2019] – [Animal studies] sallieq | ||
---|---|---|---|
Line 45: | Line 45: | ||
// | // | ||
+ | |||
+ | " | ||
===== Benefits of olmesartan for patients with kidney disease ===== | ===== Benefits of olmesartan for patients with kidney disease ===== | ||
Line 87: | Line 89: | ||
==== Animal studies ==== | ==== Animal studies ==== | ||
+ | |||
+ | [[http:// | ||
Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | ||
Line 95: | Line 99: | ||
{{tag> | {{tag> | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
+ | |||
+ | Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate < | ||